Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas

Kohshi, Kiyotaka; Yamamoto, Haruaki; Nakahara, A; Katoh, Takahiko; Takagi, Masashi

doi:10.1007/s11060-006-9283-1

Cited by 63 publications

(55 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proportion of TUNEL-positive cells was ≥60% in the control group, whereas the proportion of Ki67-positive cells was ≤10%. In addition, in a previous study (15), for subcutaneous glioma cells, the proportion of apoptotic and proliferative cells was ≥60% and ≤10%, respectively, whereas in the present study, the proportion of apoptotic cells in the intracranial glioma was ≤20%, while the proportion of proliferative cells was ≥30%. This difference may be due to the differences in the surroundings of the glioma cells.…”

Section: A B Ccontrasting

confidence: 74%

“…A number of previous studies have indicated that combining hyperbaric oxygen treatment with chemoradiotherapy may improve the prognosis for glioma patients and reduce complications (13)(14)(15)22); however, the specific mechanism by which this occurs remains unknown. A previous study proposed that hyperbaric oxygen may induce apoptosis in tumor cells and decrease the vascular density in subcutaneous …”

Section: Discussionmentioning

confidence: 99%

“…Previous studies proposed that hyperbaric oxygen stimulation prior to chemotherapy and radiotherapy may increase the efficacy of the treatment and improve prognosis, as hyperbaric oxygen may increase the oxygen content of tumor tissue (10,11). Hyperbaric oxygen stimulation of GBM patients has previously resulted in longer median survival rates and reduced side effects (12)(13)(14)(15). Temozolomide (TMZ) is a novel drug for the treatment of glioma.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hyperbaric oxygen promotes malignant glioma cell growth and inhibits cell apoptosis

et al. 2015

View full text Add to dashboard Cite

Abstract. Glioblastoma multiforme (GBM) is the most frequently diagnosed intracranial malignant tumor in adults.Clinical studies have indicated that hyperbaric oxygen may improve the prognosis and reduce complications in glioma patients; however, the specific mechanism by which this occurs remains unknown. The present study investigated the direct effects of hyperbaric oxygen stimulation on glioma by constructing an intracranial transplanted glioma model in congenic C57BL/6J mice. Bioluminescent imaging (BLI) was used to assess the growth of intracranial transplanted GL261-Luc glioma cells in vivo, while flow cytometric and immunohistochemical assays were used to detect and compare the expression of the biomarkers, Ki-67, CD34 and TUNEL, reflecting the cell cycle, apoptosis and angiogenesis. BLI demonstrated that hyperbaric oxygen promoted the growth of intracranially transplanted GL261-Luc glioma cells in vivo. Flow cytometric analysis indicated that hyperbaric oxygen promoted GL261-Luc glioma cell proliferation and also prevented cell cycle arrest. In addition, hyperbaric oxygen inhibited the apoptosis of the transplanted glioma cells. Immunohistochemical analysis also indicated that hyperbaric oxygen increased positive staining for Ki-67 and CD34, while reducing staining for TUNEL (a marker of apoptosis). The microvessel density was significantly increased in the hyperbaric oxygen treatment group compared with the control group. In conclusion, hyperbaric oxygen treatment promoted the growth of transplanted malignant glioma cells in vivo and also inhibited the apoptosis of these cells.

show abstract

Section: A B Ccontrasting

confidence: 74%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hyperbaric oxygen promotes malignant glioma cell growth and inhibits cell apoptosis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In the present study, RTOG-RPA Class was determined in 95% of patients with the greatest survival advantage appreciated by patients in Class IV: 20.2 months (Table 2) (Figure 4). In prior studies recently reviewed [38], median overall survival for all patients treated with salvage GKRS was from 16.7 to 33.2 months [15,16,18,[30][31][32][33][34][35]. It is also informative to analyze which patient characteristics predict longer survival following salvage therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Stereotactic radiosurgery has also shown to provide a survival benefit for those in which repeat surgical resection is not indicated [29]. Multiple studies have offered evidence to support a survival benefit for select rGBM patients who receive GKRS salvage treatment [15,16,18,[30][31][32][33][34][35].…”

Section: Introductionmentioning

confidence: 99%

Case Series: Gamma Knife as Salvage Therapy for Recurrent Glioblastoma Multiforme

Larson¹,

Peterson²,

Lamoreaux³

et al. 2014

Brain Disord Ther

View full text Add to dashboard Cite

Objectives: Glioblastoma multiforme is a highly malignant primary tumor of the brain. It has a dismal survival prognosis of 14-16 months following initial diagnosis. Despite aggressive upfront therapy, glioblastoma tends to recur in twelve months. Following this recurrence, some patients may benefit from Gamma Knife Radiosurgery (GKRS) treatment. This study analyzes survival outcomes in a case series by studying known prognostic indicators for glioblastoma patients.Methods: 63 patients with recurrent glioblastoma were treated with GKRS as part of a multimodal treatment plan between 2002 and 2011. Overall survival (from date of diagnosis) was compared to expected survival times as indicated by updated RTOG recursive partitioning analysis (RTOG-RPA) Classes. Survival post-GKRS salvage was also investigated. Univariate and multivariate analyses were conducted to determine whether there were significant predictors of overall survival for patients undergoing GKRS salvage. Results:Overall median survival from time of initial diagnosis was 20.2 ± 2.7 months for the entire group. 46 patients were in RTOG-RPA Class IV with a median overall survival of 20.2 ± 2.6 months (expected prognosis: 11.2 months). Median survival following GKRS salvage therapy was 9.9 ± 3.1 months for all patients. Multivariate analysis indicated that KPS was a significant predictor of survival (Hazard Ratio 0.22 compared to a KPS of 80).Conclusions: GKRS may be a safe and effective salvage therapy for selected recurrent glioblastoma patients, providing prolonged survival and quality of life compared to patients not receiving salvage treatment. Treatment options should be appropriately tailored to each patient's individual situation.

show abstract

Brain Tumors

Gains

Short

2010

Re-Irradiation: New Frontiers

View full text Add to dashboard Cite

Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas

Abstract: Gamma FSRT after HBO therapy appears to confer a survival benefit for patients with recurrent high-grade gliomas and warrants further investigation.

Cited by 63 publications

References 25 publications

Hyperbaric oxygen promotes malignant glioma cell growth and inhibits cell apoptosis

Hyperbaric oxygen promotes malignant glioma cell growth and inhibits cell apoptosis

Case Series: Gamma Knife as Salvage Therapy for Recurrent Glioblastoma Multiforme

Brain Tumors

Contact Info

Product

Resources

About